VivaMed BioVentures
Submit your computational drug invention. Get a 90-day exclusive evaluation window. If VivaMed later licenses or sells IP derived from your submission, you will receive 10% of Total Deal Revenue, capped at $1M, per our Program Rules. Patent rights automatically revert to you if we don't proceed.
The Deal
A fair, transparent pathway from computational invention to commercial success
90 Days
Exclusive evaluation window. We analyze, pitch to partners, and decide whether to pursue.
10% Revenue Share
If VivaMed licenses or sells IP derived from your work, you will receive 10% of Total Deal Revenue, capped at $1M, per our Program Rules.
Automatic Reversion
If we don't proceed within 90 days, patent rights automatically revert to you, subject to our Program Rules.
How It Works
From submission to success (or reversion)
Submit & Assign for Evaluation
You submit your computational drug invention through our portal. Upon submission, you assign the Invention to VivaMed for a 90-day exclusive evaluation period, subject to automatic reversion.
The 90-Day Evaluation Window
We analyze your data and pitch the asset to our pharmaceutical partner network. VivaMed has 90 days to file for patent protection or execute a commercial license/LOI.
Success or Reversion
If we succeed: We file a patent or execute a deal within 90 days. You will receive 10% of Total Deal Revenue (capped at $1M) from resulting licenses or sales.
If we don't proceed: Patent rights automatically revert to you after 90 days (subject to Program Rules). You are then free to pursue the idea elsewhere.
The Data Exchange
In exchange for this evaluation and potential access to our partner network, VivaMed retains a perpetual right to use the submitted computational data for internal modeling and dataset aggregation, regardless of the IP outcome. This is how we continuously improve BioAtlas and benefit all future inventors.
What We're Looking For
Computationally de-risked drug inventions that can be patented and licensed
De Novo Molecules
Novel small-molecule chemotypes
Repurposing
New indications for existing drugs
Biobetters
Half-life extension, multispecifics
Formulations
Route/delivery innovations
What "Good" Looks Like
Clear clinical edge — efficacy, safety, tolerability, or convenience advantage
Demonstrated novelty — explicit prior-art map and draft claim
Replicable from your repo — data inventory, environment files, commands
Human contribution log — who conceived what; how AI was used
High-Value Claim Types
Composition of Matter
Novel chemotypes, stereoisomers, deuterated analogs, salts/polymorphs
Prodrugs
Carrier-linked designs with unexpected gains in permeability or exposure
Formulations & Route
ER/SR depots, transdermal, inhaled, subcutaneous conversions
Method-of-Use
New indications, populations, dosing — especially biomarker-guided
Combination Therapies
Demonstrable synergy with quantified evidence
Biologics/Biobetters
Fc half-life extension (LS, YTE variants), multispecifics
What We Don't Accept
Content that includes PHI/PII, secrets, or controlled/dual-use details enabling misuse
Public postings of enabling details pre-filing (kills foreign patent rights)
Unverifiable 'black-box' claims without data lineage and reproducibility
Ideas where you are unwilling to allow VivaMed to retain the underlying data for internal R&D
Why Submit to BioVentures?
Open to All Innovators
Whether you're an independent researcher, AI scientist, or small biotech — if you have a computationally validated idea, we want to hear it.
Potential Revenue Share
If VivaMed licenses or sells IP derived from your submission, you will receive 10% of Total Deal Revenue — capped at $1,000,000 per inventor, per our Program Rules.
Pharma Network Access
We connect your inventions with pharmaceutical partners actively looking to in-license assets or solve challenge problems.
Powered by BioAtlas
Access our 490M+ row multi-omic dataset to fuel your drug discovery models and validate your hypotheses before submission.
Ready to Submit Your Invention?
Join the future of collaborative drug discovery. Your computational breakthrough could become the next life-saving therapy.